Who’s profiting from prescription overcharges?

http://www.kare11.com/mb/news/investigations/whos-profiting-from-prescription-overcharges/347424661

Investigations

Who’s profiting from prescription overcharges?

MINNEAPOLIS – Internal pharmacy records obtained by KARE 11, along with two newly filed class-action lawsuits, raise questions about whether some popular insurance plans are overcharging customers for prescription medicines and pocketing the profits.

What’s more, documents obtained during KARE 11’s yearlong investigation reveal that so-called “gag clauses” often prevent local pharmacists from disclosing lower prices, effectively keeping customers in the dark about the overcharges.  

“I think if people really knew what was going on, there’d be an uproar,” says Tim Gallagher.

 Gallagher says he saw the insurance overcharges first-hand when he worked as a pharmacist.  Now, he’s with a company that advocates for independent pharmacies.

“Patients were actually paying more than they could otherwise have paid if they were paying cash,” Gallagher told KARE 11.

KARE 11 began investigating the issue last year after we told the story of Twin Cities resident Curt Burshem.

When Burshem tried to refill a prescription for a life-saving kidney drug, he discovered his insurance copay was almost twice as expensive as just paying cash for the same medicine.

His copay was $476. The cash price, without insurance, was just $259.

“It makes me insane,” Burshem told KARE 11.

How could that be? 

A WHISTLEBLOWER SPEAKS OUT

For nearly a year, KARE 11 has been investigating, uncovering evidence that what happened to Burshem is happening more often than you think.

“In my opinion, it needs to stop,” said a working pharmacist. 

He spoke with KARE 11’s Jay Olstad on the condition we not reveal his identity.  He’s afraid of retaliation by insurance plans that, he says, are routinely overcharging customers.

Jay Olstad: “Consumers are paying more because they have insurance, in some cases?
Pharmacist: “It’s probably 20 to 25 percent of the claims.”
Jay Olstad: “A lot?” 
Pharmacist: “A lot.”

And there’s evidence it’s happening all across the country.

“These type of shell games go on all the time,” says Doug Hoey, CEO for the National Community Pharmacists Association.

He blames Pharmacy Benefit Managers, or PBMs, for price gouging. PBMs serve as the middle man between insurance providers and pharmacies. And, often, they set the price you pay.

“They dictate that price,” Hoey explained.

“COPAY” MORE EXPENSIVE THAN PAYING CASH?

Here’s how it works. When you use an insurance card, the pharmacist punches the information into the computer and the PBM spits out the amount you owe, the so-called insurance “copay.”

“They dictate what the pharmacy can sell it for,” Hoey said.

KARE 11 obtained rarely seen internal records from pharmacists. They were careful to block out private patient information. 

But you can still see how the insurance “copay” set by the PBMs was much higher than the cash price at the same pharmacy.

For example, the anti-depressant Venlafaxine:
– $67.13 with the insurance copay.
– $24.99 if you paid cash.

Another example:  Allopurinol, for kidney stones:
– $58.96 with the insurance copay.
– $40.52 if you paid cash.

We showed Doug Hoey other examples we found, including one for the common antibiotic Doxycycline.
The copay was $46.14.  The cash price was just $26.95.

“My son needed the exact same drug and the exact same thing happened,” Hoey told us. “Fortunately, I knew to ask, and I got the much less expensive price.”

But, too often, customers don’t know to ask.  And, believe it or not, pharmacists aren’t supposed to tell them.

“GAG CLAUSES” KEEP CUSTOMERS IN THE DARK

“They have these gag clauses that forbid them from talking to consumers,” Hoey explained.

Gag clauses like the one in a contract obtained by KARE 11 detail how pharmacists can get kicked out of an insurance network if they talk to the media or “sponsor’s members” – which means customers – “without prior consent.” 

That explains why pharmacists are frightened about speaking out about insurance overcharges.

“By me giving this information out, you know, I’m risking losing my contract,” said a pharmacist who agreed to speak to KARE 11’s Jay Olstad on the condition that we not use his name.

Jay Olstad: “What would happen if you were kicked out of the network?”
Pharmacist: “I mean it would literally shut the doors. It would be over.”

Those threats of retaliation even have Congress asking questions.

“If you make too much noise about this, your contract could be in jeopardy?” asked Congressman Doug Collins (R-GA) during a recent hearing. “That is not right.”

WHERE’S THE MONEY GOING?

So, if consumers are paying more for prescriptions, who’s getting the extra money?

That’s what KARE 11’s Jay Olstad wanted to know when he interviewed Doug Hoey of the National Community Pharmacists Association.

Olstad:  “Does it go to the local pharmacies?”
Hoey:  “It certainly does not go to the local pharmacies.”

In fact, Hoey says Pharmacy Benefit Managers (PBMs) and insurance companies use so-called “clawbacks” to pocket the extra money. 

He says “clawbacks” are when PBMs tell local pharmacies to collect a copay, but require them to return much of that money to the insurance plan.

A current pharmacist gave KARE 11 an example of how the “clawback” process works.

“A clawback is what they’re referred to,” he explained. “An insurance company may charge the patient, say, $20 in a copay.  But then they ‘clawback’ $16.  So the pharmacy ends up with a net $4.”

WHO’S PROFITING FROM CLAWBACKS?

So, who’s cashing in from prescription clawbacks?  Doug Hoey says two companies with Minnesota connections are.

“Optum and Catamaran are the two who most frequently use the consumer clawback tactic,” he said.

And who are those companies owned by?

“They’re owned by United Health, which obviously has a big presence here in the Twin Cities,” Hoey said.

In fact, KARE 11’s investigation documented examples in which customers purchasing prescriptions through UnitedHealth Group companies, to treat conditions including heartburn, depression and high blood pressure, were charged more in copays than they would have if they’d simply paid cash.

CLASS-ACTION LAWSUITS FILED

Two class-action lawsuits filed just last month accuse UnitedHealth Group of a “scheme to defraud” customers in connection with prescription copay pricing.

The lawsuits claim UnitedHealth Group and its related companies used “gag clauses” to try to keep its so-called “clawback scheme” secret.

KARE 11 asked to sit down with representatives from UnitedHealth Group for an on-camera interview about allegations that the company had overcharged customers.

UnitedHealth Group declined our request. In emails, the company said the lawsuit “has no merit.”

“Our pharmacy offerings will help customers and consumers save billions in prescription drug costs this year alone. Pharmacies should always charge our members the lowest amount outlined under their plan when filling prescriptions,” UnitedHealth Group said in a statement.

They added, that customers should never pay more than the cash price. But the email didn’t explain why some copays did cost more than just paying cash.

Retired pharmacist Tim Gallagher thinks consumers should demand changes.

“People are getting taken advantage of, pharmacies are getting underpaid, and the PBMs are laughing all the way to the bank,” he said.

Here’s the tough part for insurance customers. Paying cash may not always save you money because experts say those purchases generally don’t count toward your insurance deductible.

HOW TO COMPARE PRICES

If you do want to consider paying cash, consumer advocates recommend shopping around.

Consumer Reports posted an article earlier this year with tips about finding the best prescription drug prices.  

They recommend always asking your pharmacist, “Is this your lowest price?”

In addition, there are a number of private websites that allow you to check prescription prices and to find discount coupons at pharmacies in your area. Two of them are GoodRX.com and Lowestmed.com.

If you discover your insurance copay is more expensive than the cash price for the same prescription, we’ll like to hear about it. You can email us at investigations@kare11.com.

In the debate over opioid addition, there’s one group we aren’t hearing from: chronic pain patients, many of whom need to use the drugs on a long-term basis

War on prescription drugs: what if you depend on opioids to live a decent life?

https://www.theguardian.com/us-news/2016/jul/12/prescription-drugs-what-if-you-depend-on-opioids-chronic-pain

The US is facing what many are describing as an opioid crisis, with growing numbers of deaths associated both with opioid medications and overdoses on heroin – 19,000 in 2014 linked to opioids alone. But in the swirl of debate over the subject, there’s one group of Americans we aren’t hearing from: chronic pain patients, many of whom need to use opioids on a long-term basis to control their pain effectively.

Unlike patients with acute, short-term pain or pain associated with terminal illnesses such as cancer, they’re looking at a lifetime of living with conditions such as Ehlers-Danlos syndrome, fibromyalgia and endometriosis, along with many other disorders associated with chronic pain. Others are dealing with persistent pain from injuries.

Many have conflicted relationships with the medications they need to enjoy a good quality of life, and they fight an tough battle against negative public perception and cultural attitudes. They’re struggling with issues that aren’t being accounted for in conversations about dependence, addiction and the safe use of opioids for long-term pain management.

Heather Ace Ratcliff, who has Type 3 Ehlers-Danlos, a connective tissue disorder characterized by hypermobility which allows her joints to dislocate and subluxate easily, says uninformed views can stigmatize chronic pain patients who are struggling to access relief. “I am regularly treated as if I am overreacting, a hypochondriac, or a drug addict for wanting an increase in pain management,” she says, illustrating the consequences of misinformation about opioids and pain.

But those attitudes are internalized as well. Even though many patients recognize that opioids help them manage pain effectively, some still fear them, worrying that their relationship with their medication may be sliding into addiction. At the same time, they’re dealing with side effects like fatigue, “brain fog” and gastrointestinal stress. In an environment where physicians who aren’t extensively familiar with pain management and opioids can leap to conclusions, it can be difficult for patients to have honest conversations with their doctors about their concerns, as they may fear being chastised or cut off.

Shayla Maas, another patient with Type 3 Ehlers-Danlos who also has an autoimmune disorder, says that the conversation surrounding opioids sometimes makes her paranoid about her medications. “Maybe I’m just blowing it out of proportion,” she says, “looking for attention, looking for meds.” She can hardly be blamed for her self-doubt, as that’s precisely the kind of messaging she receives as a chronic pain patient, and it’s easy to internalise the fear, she says, that you might become a “dope fiend”.

Anna H, a patient with fibromyalgia, shares these worries. “I’ve been taking relatively small doses of pain meds every day for about six years, but I’m still afraid that taking a certain amount of pills – even if I’m in a lot of pain – will send me down the path of addiction.”

Their fears are to some extent grounded in reality: opioid medications can have an addicting effect. But the real story is more complicated.

“Opioids are the cornerstone of the treatment of pain,” explains doctor Anita Gupta, a board-certified anesthesiologist, pain specialist, pharmacist and vice-chair of Drexel College of Medicine’s division of pain medicine in Philadelphia. Among her many roles, she also serves as vice-chair of the American Society of Anesthesiologist’s ad hoc committee on prescription opioid abuse and has a vested interest in addressing the misuse of opioids. But she also has concerns about inadequate information that harms both patients and providers.

Gupta makes an important distinction between dependence and addiction, cutting to the heart of one of the greatest misunderstandings in the conversation about pain management. “If you’re on opioid medication for a long period of time, you become dependent,” she explains. “When a need becomes a want, that is really an example of when someone can become addicted. When you want it and you can’t live without it, can’t survive without it, it interrupts your day to day life, that’s addiction.”

Though organizations like the American Academy of Chronic Pain Management, US Pain Foundation and the American Chronic Pain Association engage in patient advocacy work, it can be a struggle. Even with the weight of patients, family, and medical providers behind these groups, they aren’t always treated as stakeholders in processes like developing new guidelines for opioid prescription and use.

“There’s a saying that goes something like: ‘We are all one drink or pill away from addiction,’ and I know this is meant to destigmatize what addicts go through, but I feel like I’ve been seeing variations on this ‘common knowledge’ more and more lately being used (on social media) as a cudgel to remind patients to not overdo it,” Anna says, speaking to the dual-edged sword of awareness. A motto designed to humanize the experience of addiction has been turned into a weapon that targets people who rely on opioids for pain management, and that translates to real-world stigma.

“When other people find out that I’m on opioids,” Maas explains, “depending on how close they are and how well they know me, I might get an ‘it sucks that your pain is so bad’ to a slightly narrowed side eye.” The judgmental comments she receives make her feel like people think she’s taking opioids for the fun of it.

“Believe me,” she says, “this is not for fun.”

“I haven’t really experienced the stigma personally other than some ill-informed comments from acquaintances,” says Anna. “But the media coverage of the ‘opiate epidemic’ as driven by pill pushing-doctors and by pain patients worries me a lot, and I think it is already being used to forward the idea that people in chronic pain should not have access to relief from their pain.”

Both Maas and Anna articulate worries that chronic pain patients are being “thrown under the bus”. Doctor Jerrold Winter, professor of pharmacology and toxicology at the University at Buffalo, tends to agree, and is concerned that new CDC guidelines and other efforts to address opioid use could actually make the situation worse.

“I think [the CDC guidelines] go much too far and a) will leave many in pain and b) will drive some seeking pain relief into the illicit market with all its hazards,” he says. “Indeed, two NIDA officials recently pointed out that the rate of deaths from prescription opiates between 2011 and 2013 were stable while heroin-related death rates rose dramatically. I fear that this trend will only worsen under the CDC guidelines.”

The ability to be open about these symptoms along with concerns about degree of dependence on opioid medication will help patients make sound decisions about their care.

That requires both clinician and patient education, as well as listening to the fears of chronic pain patients like Maas and Ratcliff as they attempt to balance chronic pain, fears about forming addictive habits and frustration with public perception. Both doctors and patients need to be playing a more prominent role in the unfolding conversation about how to deal with a very real American public health crisis.


CDC previously reported a rise in new hepatitis C infections

A syringe is pictured in downtown Austin, Indiana, in this photo. Drug epidemic stalls HIV decline in whites who shoot up

http://www.foxnews.com/us/2016/11/29/drug-epidemic-stalls-hiv-decline-in-whites-who-shoot-up.html

The long decline in HIV infections among white people who inject drugs has stalled, another grim side effect of the nation’s drug abuse epidemic.

Health officials released the news Tuesday, as part of a call for more use of needle exchange programs.

“We really risk stalling or reversing decades of progress on HIV transmission,” said Dr. Tom Frieden, director of the Centers for Disease Control and Prevention.

The report comes as the nation is facing an ongoing epidemic of opioid and heroin use that has led to an increase in drug overdose deaths, particularly among white people. The increase in drug abuse is also hampering efforts to slow diseases carried in the blood that can be spread when injection drug users share needles.

1 IN 7 PEOPLE WITH HIV IN EU UNAWARE THEY HAVE THE VIRUS

The CDC previously reported a rise in new hepatitis C infections, which is tied largely to injection drugs.

Most cases of HIV, the virus that causes AIDS, are transmitted through sex — only about one in 11 HIV infections diagnosed each year are among people who inject drugs. But sharing dirty needles can spread HIV much more quickly.

More than 100 injection drug users were infected with HIV in early 2015 in rural Scott County, Indiana. The state’s governor at the time — Mike Pence, now the vice president-elect — declared a public health emergency and authorized a limited need-exchange program to prevent the virus from spreading further.

Until recently, HIV cases in injection drug users had been falling for all racial groups. Cases still are falling in blacks and Hispanics. But for whites they stopped falling in 2012.

NEW HIV VACCINE TRIAL TO START IN SOUTH AFRICA

In 2014, for the first time, a larger number of white inject drug users were diagnosed with HIV than injection drug users in any other racial or ethnic group. Traditionally, far more cases were seen in urban blacks.

At least part of the reason is that white injection drug users are often younger and more likely to share needles, according to a 22-city CDC study of people who inject drugs. Nearly half of white injection drug users shared needles with other addicts in 2015, compared with a third of Hispanics and a fifth of blacks.

Needle exchange programs give out clean syringe needles in exchange for used ones. Medical experts have found that such programs cut down transmission of HIV and do not cause increases in drug use.

Congress, though, has gone back and forth on allowing the federal government to fund the programs. For now, federal funds can be used for some program costs, but not for the purchase of sterile needles or syringes.

 

Survey Of ER/Trauma Health Care Professionals Finds No Evidence Of Either Kratom Deaths Or Epidemic Of Abuse

Survey Of ER/Trauma Health Care Professionals Finds No Evidence Of Either Kratom Deaths Or Epidemic Of Abuse

military-technologies.net/2016/11/29/survey-of-ertrauma-health-care-professionals-finds-no-evidence-of-either-kratom-deaths-or-epidemic-of-abuse/

WASHINGTON, Nov. 29, 2016 /PRNewswire-USNewswire/ — If the DEA is correct in suggesting that there is a kratom epidemic going on in America, then it is somehow happening without our nation’s front-line medical professionals knowing a thing about it. A random online survey of 115 emergency room (ER) and trauma health care professionals across the U.S. found zero reported cases of deaths related to kratom. The new poll also uncovered precisely 0 percent support among those surveyed for a Drug Enforcement Administration (DEA) ban on the coffee-like herb kratom.

 

Available online at http://bit.ly/kratomdocpoll and conducted via SurveyMonkey, the American Kratom Association (AKA) poll was carried out between November 23-28. 

AKA is submitting the survey findings as a formal response to the request for kratom-related comments from the DEA, a process that closes at 11:59 p.m. on December 1st.

American Kratom Association Founder Susan Ash said: “We conducted this survey after ER doctors and other medical professionals told us the notion there is some kind of kratom epidemic going on in America is a hoax. In fact, our totally random online survey found no evidence of kratom-related deaths and zero support among America’s front-line medical professionals for a ban on kratom. We are not going to stand idly by and let the DEA or anyone else whip up a phony panic about a nonexistent epidemic to try and ban a legal product that’s being consumed responsibly, with no major problems, by three-five million Americans.”

Key survey findings include the following:

The random online survey conducted via SurveyMonkey focused on panel of ER/trauma doctors, surgeons, nurses, related health care professionals, and EMTs/paramedics. Invitations to participate in the survey were extended directly through LinkedIn groups (including EMS Leadership and Administration, Emergency Room RNs and Management, Emergency Medicine and EMS World) and Facebook groups (including Paramedics on Facebook, FRCS Trauma & Orthopedic Surgery, First Responders, Trauma, Critical Care, and Acute Care Surgery, and Emergency Medical Technician). The full results and the complete text of the survey instrument are available online at http://bit.ly/kratomdocpoll.

ABOUT AKA

The America Kratom Association, a consumer-based non-profit organization, is here to set the record straight, giving voice to those suffering and protecting our rights to possess and consume kratom. AKA represents tens of thousands of Americans, each of whom have a unique story to tell about the virtues of kratom and its positive effects on their lives. www.americankratom.org

NO GOOD DEED… goes unpunished ?

PA Dumpster Divers Arrested For Helping Their Community

http://www.huffingtonpost.com/zac-thompson/dumpster_divers_arrested_b_13209010.html

The average person creates an incredible amount of waste on a daily basis and the average grocery store is even worse. The amount of perfectly good food that goes to the garbage is far too high now that we’re living in an era of convenience. The United States throws away 165 billion dollars of food a year, which means over 30% of the food purchased in the US ends up in the trash. So next time you think about throwing out food, don’t. Make a sauce with those musty old tomatoes.

You can also combat food waste by getting inside a dumpster. Dumpster diving is a popular form of modern salvaging that helps environmental activists reclaim food waste. While you might cringe at the idea, It’s a great way for people to prevent good food from heading to the landfill. Don’t believe us? Check out our previous coverage on Rob Greenfield.

Rob Greenfield has launched a new campaign raising awareness around Tony Moyer and Sam Troyer, brothers-in-law who were recently arrested for diving in a dumpster at a CVS store in Hershey, PA. Although the dumpster is located in an open enclosure in a parking lot in plain sight, with no “No Trespassing” signs or locks, the men were charged with loitering and prowling at night as well as criminal trespassing.

 The video above shows that the pair have collected thousands of dollars worth of edible food from dumpsters and donate it all to people in need, with donation receipts to prove their intent.

Dumpster diving prevents food waste, plain and simple. It’s not something we should punish but it is something we should reward. Help spread the word about Tony and Sam and together we might be able to change the dialogue surrounding dumpster diving to the actual issue at hand: food waste.

Dr Carlos Sullivan of Butte died recently and suddenly: more chronic pain pts abandoned !

stevemailbox

Dr Carlos Sullivan of Butte died recently and suddenly.
He was carrying some patients on pain meds for their long term chronic pain.

Some of these patients have come to me to see if I could help them. I just received a call from the ER in Butte, looking to help a patient who lost access, and no one in Butte will see these patients.
Our profession stands powerless to help these people?

It seems to me that if the good people of Butte were out of food or water,
We have organizations like the Red Cross to help.

If the town was burning, we have interagency agreements, and we would be down there helping.

If some type of infectious disease struck, the health department would respond.

Who responds for patients who suffer from sudden abandonment?
Patient who will withdraw?
Become suicidal?

What obligation does our profession have to respond to a clear public health crisis?

I would like to propose a “doctors without borders” response to this.

But I do not know who to even approach about it.

DPHHS?
Montana human rights groups?
Montana Medical association?
The hospital association?
The Governor?

Since this opiate issue appeared, there still has not been any overarching policy approach to address the unintended consequences of having people on pain medications for decades then dropping them suddenly.

I do not see how I can help, by myself, without sharing the risk and burden with the rest of the profession.

Any suggestions?

Thank you.

PS: while posting this I got another call from another patient in butte who lost access.
What are people supposed to do?

Kratom may be safer and less addictive than current treatments for pain, research suggests

Kratom may be safer and less addictive than current treatments for pain, research suggests

http://www.news-medical.net/news/20161129/Kratom-may-be-safer-and-less-addictive-than-current-treatments-for-pain-research-suggests.aspx

A delayed U.S. Drug Enforcement Administration ban on kratom would stifle scientific understanding of the herb’s active chemical components and documented pharmacologic properties if implemented, according to a special report published today in The Journal of the American Osteopathic Association.

The report cited the pharmacologically active compounds in kratom, including mitragynine, 7-hydroxymitragynine, paynantheine, speciogynine and 20 other substances, as one basis for further study. It also emphasized the extensive amount of anecdotal evidence and current scientific research that indicates kratom may be safer and less addictive than current treatments for pain and opioid withdrawal.

“There’s no question kratom compounds have complex and potential useful pharmacologic activities and they produce chemically different actions from opioids,” said author Walter Prozialeck, chairman of the Department of Pharmacology at Midwestern University Chicago College of Osteopathic Medicine. “Kratom doesn’t produce an intense euphoria and, even at very high doses, it doesn’t depress respiration, which could make it safer for users.”

Kratom (Mitragyna speciosa) is indigenous to Southeast Asia, where the plant was used for centuries to relieve fatigue, pain, cough and diarrhea and aid in opioid withdrawal. Currently sold in the United States as an herbal supplement, kratom drew DEA scrutiny after poison control centers noted 660 reports of adverse reactions to kratom products between January 2010 and December 2015.

“Many important medications, including the breast cancer treatment tamoxifen, were developed from plant research,” said Prozialeck.

“While the DEA and physicians have valid safety concerns, it is not at all clear that kratom is the culprit behind the adverse effects,” said Anita Gupta, DO, PharmD and special advisor to the FDA.

Dr. Gupta, an osteopathic anesthesiologist, pain specialist and licensed pharmacist, has treated a number of patients who’ve used kratom. “Many of my patients are seeking non-pharmaceutical remedies to treat pain that lack the side effects, risk, and addiction potential of opioids,” she said.

Kratom is currently banned in states including Alabama, Florida, Indiana, Arkansas, Wisconsin and Tennessee. The DEA is scheduled to decide whether to place kratom on its list of Schedule 1 drugs, a classification for compounds thought to have no known medical benefit. Marijuana, LSD and heroin are Schedule 1 drugs, which prevents the vast majority of U.S.-based researchers from studying those substances.

Police: Suburban drug users take fatal risks to score drugs in Indy

Police: Suburban drug users take fatal risks to score drugs in Indy

http://fox59.com/2016/11/28/police-suburban-drug-users-take-fatal-risks-to-score-drugs-in-indy/

INDIANAPOLIS, Ind.– Detectives aren’t yet certain what Evans Johnson and Jessica Downey were doing in the vicinity of 23rd and Adams Streets the night before Thanksgiving, but whatever it was, they paid for the excursion with their lives.

Johnson listed a home address in Camby in extreme southwest Marion County. Downey was from rural Vincennes. They were found shot to death miles away in an east side neighborhood known for drug dealing and violence.

“We do have a big problem on North District with people using these landmark locations to come down here to buy dope from outside the county, Hendricks County, Hamilton County, Hancock County, because they know they can get dope in these neighborhoods and we gotta try to change that,” said IMPD District Commander Chris Bailey.

The killings of Johnson and Downey happened just blocks from Bailey’s post.

Investigators say recent high-profile drug raids, and everyday pressure applied by district narcs like those working for Commander Bailey, have disrupted entrenched drug operations and taken guns and money off the streets, leading dealers to more violence and users to even riskier behavior to feed their addictions.

“These guns in the hands of felons, in the hands of drug dealers, in the hands of people who should not possess any kind of weapon, we’re getting guns everyday out of these houses when we interact with these folks,” said Bailey. “To me that is a bigger impact when we talk about violent crime because every gun we take out of the hands of a felon or a person who is not supposed to have a gun, in my opinion whether I’m able to prove it or not, we prevent a violent crime in this city.”

On Nov. 17, 700 FBI agents, local police and ISP troopers raided 40 locations in search of 23 suspects indicted in a massive methamphetamine conspiracy stretching from Indianapolis to Sinaloa, Mexico.

Along with 15 pounds of meth and $55,000 cash, investigators seized 70 guns.

Authorities arrested a man they believed to be the cartel’s main operator in Indianapolis while taking off another dealer Bailey said he recalled chasing during his days as a narcotics detective nearly ten years ago.

And while IMPD now regularly touts the type of drug, weapons and cash seizures that were typical and unreported just a year ago, Bailey said investigators are frustrated by the return of suspects to their neighborhoods in the days after the busts.

“We have over 220 open complaints just on North District alone of people that the neighborhood believes they are selling narcotics.”

Fliers urging witnesses to call Crimestoppers about the Johnson and Downey murders are already up on stop signs and abandoned houses on North Adams Street.

Just blocks away, detectives are also investigating the shootings of a man and a woman in the 1900 block of Dearborn Street where violence and drugs are also common plagues.

Why does #Walgreens charge 1,237% more than Costco?

Why does Walgreens charge 1,237% more than Costco?: Laurie Roberts

http://www.usatoday.com/story/opinion/nation-now/2016/11/27/why-does-walgreens-charge-1237-more-than-costco-laurie-roberts/94486422/

Walgreens is charging $198.80 out-of-pocket for a thirty-day supply of Donepezil – a medication used to treat Alzheimer’s. The same medication at Costco costs $14.87. Why? We asked the companies.

Apparently, pricing strategy for prescription drugs is a state secret akin to the nation’s nuclear codes.

PHOENIX — Corinne was reeling when she left the doctor’s office and made a beeline to her neighborhood Walgreens.

Ken, her husband of 38 years, had just been diagnosed with Alzheimer’s. She had watched, stunned and near tears, as he couldn’t answer a series of questions, couldn’t even tell the neurologist that it was fall.

A blow like that? It’s almost physical, like a freight train slamming into your gut as suddenly you realize that life will never again be the same.

“We left the office with a prescription for Donepezil,” she told me. “I dropped it off at Walgreens and came on home with our daughter and Ken. A couple of hours later, she and I went to pick it up. This was when I found the price to be $198.80. I was floored, but my overwhelming thought was ‘Get that medicine into Ken ASAP.’ ”

She paid cash, as Ken is on Medicare but doesn’t have prescription drug coverage. A few days later, when some of the fog of emotion had lifted, Corinne started questioning how 30 tablets — a month’s supply — could cost $198.80. So she started checking around.

And found the same medication at Costco for $14.87.

So I guess you’re wondering how Walgreens could charge $198.80 for pills that cost just $14.87 at Costco. How a reputable pharmacy could gouge its customers to the tune of 1,237%.

Corrine wondered as well. She wrote Walgreens but never got an explanation — just a call offering a full refund.

Why do they charge so much? It’s a secret 

Apparently, pricing strategy for prescription drugs is a state secret akin to the nation’s nuclear codes. Neither Costco nor Walgreens would discuss it with me.

“It’s important to note that more than 97% of our patients do not pay cash prices,” Walgreens spokesman Scott Goldberg told me, via email. “They purchase their prescriptions using some form of prescription insurance coverage.”

So, reading between the lines, the people who have insurance get a break on the cost and the people who don’t, the ones who often can’t afford insurance, are gouged?

Apparently, it works like this. Most customers of the major chain drug stores have insurance, and insurance companies negotiate prices that are discounted from a store’s list price. Therefore, the chains attach the list price to a rocket and launch it skyward — and to heck with the poor schlubs like Corrine, who pay out of pocket.

Which doesn’t explain why Costco’s prices remain earthbound. And mum’s the word over at Costco HQ:

“Costco Pharmacy prices pharmaceuticals based on the same philosophy that we apply to the other merchandise we sell in the warehouse which is — ‘To continually provide our members with quality goods and services at the lowest possible prices.’ However we typically do not share the details behind this philosophy or business model.”

The moral of this story: It’s worth shopping around for prescription drugs. Because that neighborhood drug store that bills itself as “at the corner of happy and healthy?”

Turns out it’s on a street called highway robbery.

Healthcare provider, UnitedHealth Group, the largest health insurer in the U.S., has reportedly been overcharging its customers for secretly overcharging them for prescription drugs, according to Reuters. Time

Alzheimer’s Drug Shows Promise for Reducing Fibromyalgia Pain

Alzheimer’s Drug Shows Promise for Reducing Fibromyalgia Pain

nationalpainreport.com/alzheimers-drug-shows-promise-for-reducing-fibromyalgia-pain-8832170.html

Fibromyalgia warrior Angela Holt has one of the most popular crafting channels on YouTube with some of her tutorials garnering more than a half million views.

But about a year ago, Holt was struggling to stay active in the online crafting community. The pain and restlessness in her legs were so intense that she often couldn’t sleep at night, and it was affecting her ability to craft and make videos.

 

“I just didn’t feel like doing it,” she said. “I was hurting too bad. My legs were hurting or something else was hurting. I’d just lose interest.”

Holt was diagnosed with fibromyalgia in early 2014. Like so many others with fibromyalgia, she was prescribed a series of prescription drugs that did little to lessen the pain. Percocet helped, but it left her in a fog. In desperation, she sought the advice of her primary-care physician, Dr. Robert Holston from Holston Family Practice in the small town of Cross Plains, Tennessee.

Unlike some physicians, Holston intimately knew all about the challenges of living with fibromyalgia. His wife has had it for 25 years, so he has a special interest in the condition.

Last year, Holston stumbled upon a Family Practice News article reporting the results of a small Spanish study using memantine (sold under the brand name of Namenda), a common Alzheimer’s drug, for fibromyalgia. The randomized, double-blind study compared memantine to placebo in 63 fibromyalgia patients. After six months, those in the memantine group reported less pain and a higher pain tolerance than the placebo group. The most common side effects were dizziness (25.8%) and headache (12.9%).

“When I read this article about Namenda, it made sense to me because it blocks the glutamate neurotransmitter, which is so common in the brain, and it slows transmission into the neurons. I think high levels of glutamate in the brain, for whatever reason it’s there, causes a perception of chronic body pain. In blocking the neurotransmitter glutamate, it tends to reverse or cool off the nervous system’s reaction.”

There are very few medications approved to treat fibromyalgia, and none of them work very well, so Holston began prescribing memantine to a few of his toughest fibro patients, like Holt, to see if it might help.

“Immediately, the first week I could tell a huge difference,” Holt said. “The brain fog was gone. The pain … was still there, but it wasn’t as intense, and the restlessness of my legs … was completely gone. I can remember stuff now. I’m not like a zombie. I can function! And then I was able to drop down to only taking Tramadol. I still have pain medication, but I’m not needing much at all hardly like I used to.”

Holt’s symptoms improved so much that she decided to share her experience with memantine on her YouTube channel. She considers her fibromyalgia to be mostly under control now.

Holston’s wife also has improved using memantine.

“[Memantine] reversed her fibromyalgia actually,” Holston said. “It had such a dramatic effect on her body pain. All of it went away except for the [pain related to] weather changes. It’s put her fibromyalgia in remission. It was like a miracle for her.”

But like every fibromyalgia treatment, memantine appears to only work in some patients.

“I’ve had at least 30 patients on Namenda, and the results have been variable,” Holston said. “If it works, it works beautifully. I’m just amazed by the results I see in the patients that have them. I would say a good 70 percent of my patients have had positive results.”

Dr. Ginevra Liptan, founder of the Frida Center for Fibromyalgia near Portland, Oregon, has also started using memantine in some patients.

“Quite a few patients of mine have registered significant pain reduction on memantine,” Liptan said. “It seems to work for about 60 percent of my patients who have tried it. Clinically, I have found [memantine] to be most helpful in patients on high dosages of opiates but still having high levels of pain. Since it works on a different pathway than the opiates, it can have an additive benefit. One of my patients had such significant pain improvement with Namenda that she was able to cut her opiate medication in half.

“The other group of patients I often use it for are those really struggling with high levels of both pain and fibro fog, as it can help both issues. NMDA [N-methyl-D-aspartate] receptor blockers [like memantine] were actually originally developed to treat Alzheimer’s dementia, not pain, so it can also help improve cognitive function for some patients.”

Dr. Jon Ebbert, professor of medicine with the Mayo Clinic, authored the previously mentioned Family Practice News article and says memantine deserves more study.

“There seems to be some accumulating evidence for memantine to be effective for pain, but we’re going to need bigger trials to be sure,” he said. “It’s worth investigating. We don’t have a lot of good options [for chronic pain] other than the opioids. … These are the kind of investigations – this sort of drug repurposing – that need to continue to happen, especially with pain.”

Unfortunately, since memantine is a generic drug, it’s unlikely to draw the interest of the pharmaceutical companies that perform most larger studies. That leaves memantine’s future as a potential fibromyalgia treatment in the hands of physicians who are forward-thinking enough to try something different.

“Absent wealthy angels who care about our patients, such studies won’t likely get done,” said Dr. Richard Podell from the Podell Medical Practice in Summit, New Jersey. “The only way we are likely to learn more is for doctors and patients to use it and then report their data to places where other doctors and patients can see the results.”

Podell has prescribed memantine to five of his fibromyalgia patients so far and recently reported the outcomes in a blog post. Two patients had moderate improvement, two had no improvement and one could not tolerate the drug at full dose.

Memantine’s cost is another barrier for patients.

“The biggest challenge I find as a clinician prescribing Namenda is that it is quite expensive and is only FDA approved to treat dementia, so using it for fibromyalgia is considered off label and not covered by many insurance plans,” Liptan said. “I often have to argue quite extensively with insurance companies to try to prove to them why they should cover it. Sometimes I am able to successfully appeal the denial and sometimes not.”

Still, the results from the 2014 Spanish study definitely warrant more research. Based on anecdotal reports, it could be the miracle some fibromyalgia patients are seeking.

For more information on using memantine/Namenda for fibromyalgia, visit the following:

Efficacy of memantine in the treatment of fibromyalgia: A double-blind, randomised, controlled trial with 6-month follow-up (2014 Spanish study)

Namenda (memantine): A potential new treatment for fibromyalgia

Fibromyalgia: Memantine reduced pain in small, blinded trial

Combined use of pregabalin and memantine in fibromyalgia syndrome treatment: A novel analgesic and neuroprotective strategy?